In conclusion, Acly is crucial for IL-4-induced mouse macrophage activation, and myeloid-specific KO of Acly slightly affects tumor immune composition and TAM phenotype without affecting tumor growth, suggesting that cancer therapies targeting Acly do not negatively affect TAMs. The gene discussed is ACLY; the disease is neoplasm.